Search
Gilead Sciences Inc
GILDAdd to Watchlist
127.250USD
+2.950+2.37%
Close 06/16, 16:00（ET）Quotes delayed by 15 min
157.96BMarket Cap
17.17P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.37%
5 Days
+1.39%
1 Month
-1.80%
6 Months
+7.13%
Year to Date
+3.67%
1 Year
+14.82%
Key Figures
125.660Open
128.175High
9.38MVolume
17.17P/E TTM
13.06P/E Dynamic
3.190Dividend TTM
0.76%Turnover Ratio
124.300Prev. Close
124.140Low
904.04MTurnover
329.26P/E Static
6.72P/B
2.51%Div Yield TTM
16.35%ROA
157.29052wk High
1.19Volume Ratio
480.00MNet Profit
1.24BShares
7.4127EPS TTM
0.34Beta
43.19%ROE
104.46052wk Low
3.25%Amplitude
79.24%Gross Margin
157.96BMarket Cap
-2.76Reward/Risk
1.50%Risk Rate
TradingKey Stock Score of Gilead Sciences Inc
Currency: USD Updated: 2026-06-16Key Insights
Gilead Sciences Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 9 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 158.05.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Gilead Sciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Gilead Sciences Inc Highlights
StrengthsRisks
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It operates in more than 35 countries worldwide.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 29.44B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 814.79%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 814.79%.
Undervalued
The company’s latest PE is 17.16, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.14B shares, decreasing 0.22% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Analyst Rating
Based on
32
analysts
Buy
Current Rating
158.050
Target Price
+25.85%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Gilead Sciences Inc Info
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It operates in more than 35 countries worldwide.
Ticker SymbolGILD
CompanyGilead Sciences Inc
CEOO'Day (Daniel P)
Websitehttps://www.gilead.com/
Related Instruments
-0.60%
-0.17%
+0.41%
-0.41%
+0.30%
+0.84%
-0.79%
+0.15%
-0.82%
+0.63%
-0.53%
+0.58%
+0.01%
+0.74%
0.00%
-0.05%
-0.63%
+0.65%
-0.70%Popular Instruments
75.080
+0.040 (+0.05%)
299.330
+2.910 (+0.98%)
207.290
-5.160 (-2.43%)
4327.380
-3.780 (-0.09%)
681.180
+27.650 (+4.23%)
1992.150
-115.710 (-5.49%)
1020.770
-67.220 (-6.18%)
373.430
+4.080 (+1.10%)
64918.430
-905.570 (-1.38%)
404.760
-6.390 (-1.55%)
FAQs
What is the current price of Gilead Sciences Inc (GILD)?
The current price of Gilead Sciences Inc (GILD) is 127.25.
What is the symbol of Gilead Sciences Inc?
The ticker symbol of Gilead Sciences Inc is GILD.
What is the 52-week high of Gilead Sciences Inc?
The 52-week high of Gilead Sciences Inc is 157.29.
What is the 52-week low of Gilead Sciences Inc?
The 52-week low of Gilead Sciences Inc is 104.46.
What is the market capitalization of Gilead Sciences Inc?
The market capitalization of Gilead Sciences Inc is 158.04B.
Is Gilead Sciences Inc (GILD) currently rated as Buy, Hold, or Sell?
According to analysts, Gilead Sciences Inc (GILD) has an overall rating of Buy, with a price target of 158.05.
What is the Earnings Per Share (EPS TTM) of Gilead Sciences Inc (GILD)?
The Earnings Per Share (EPS TTM) of Gilead Sciences Inc (GILD) is 6.84.
